Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...
Use of biologics significantly reduced exacerbations and hospitalizations in adults with chronic obstructive pulmonary disease (COPD) and overlapping type 2 asthma inflammation, based on data from a ...
Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...
Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people globally ...
Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according to a study presented at CHEST 2024, the ...
In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 BOREAS trial included adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results